cerca CERCA
Giovedì 01 Dicembre 2022
Aggiornato: 12:26
Temi caldi

Comunicato stampa

Merck Millipore's guava easyCyte™ 12 Flow Cytometer Offers Improved Resolution Down to 0.2 um

06 novembre 2014 | 19.49
LETTURA: 3 minuti

- Increased performance provides better sensitivity and resolution

- Significant improvement over typical flow cytometers' resolution limits

- Aids in the analysis of small particles, beads, bacteria and algae

DARMSTADT, Germany, Nov. 6, 2014 /PRNewswire/ -- Merck Millipore, the Life Science division of Merck, offers new data demonstrating improved performance for its guava easyCyte™ 12 flow cytometer, a simple and powerful benchtop method for multicolor flow cytometry. The system has been shown to detect particles as small as 0.2 um, a significant improvement over typical flow cytometers.

This increase in performance gives researchers better sensitivity and resolution for their experiments. Improved sensitivity provides better separation, making gating and identifying dimmer populations easier. In addition, resolution down to 0.2 um opens up new application areas, particularly for researchers analyzing small particles and beads, as well as studying bacteria or algae.

"Merck Millipore has recognized the need for an advanced generation of powerful benchtop flow cytometers to enable today's researchers to measure multiple molecular pathways and biomarkers at a cellular level," said Patrick Schneider, Ph.D., Head of Merck Millipore Bioscience Business Area. "Our new performance data clearly demonstrate that guava easyCyte™ 12 flow cytometers can provide better resolution than traditional systems on the market, allowing scientists to achieve very powerful cellular analysis right at the benchtop."

The guava easyCyte™ 12 flow cytometer uses three excitation lasers to detect up to 12 parameters simultaneously, including 10 fluorescent colors plus forward and side scatter for size and granularity determination. The upgraded lasers and unique scanning technology reduce channel bleedover and significantly improve resolution. Single-sample and multi-sample processing options are offered, and high-throughput analysis is possible with robotic sample trays that automatically handle 96-well micro­plates and up to 10 sample tubes. The new platform consumes less sample, generates less waste and is easier to maintain than traditional systems, enabling researchers to save time and money while conducting comprehensive cell analysis.

The system, capable of detecting mammalian and micro­bial cells and beads, offers an intuitive interface at an affordable price for every laboratory budget. As with all of Merck Millipore's guava easyCyte™ systems, a sample of fluorescently labeled cells is aspirated into a microcapillary flow cell, which eliminates the need for sheath fluid and provides absolute cell counts. In addition, the flow cell is self-aligning and user-replaceable, reducing downtime and service visits.

For more information, please visit www.merckmillipore.com/guava.

About Merck Millipore Merck Millipore is the Life Science division of Merck and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, Merck Millipore serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 66 countries and 2013 revenues of €2.6 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.

For more information, please visit www.merckmillipore.com.

About MerckMerck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Riproduzione riservata
© Copyright Adnkronos
Vedi anche
ora in
Prima pagina
in Evidenza